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Biological mechanisms associated with response to trauma may impact risk for depression. One such mechanism
is endocannabinoid signaling (eCB), a neuromodulatory system comprised of the CB1 subtype of cannabinoid
receptors (CB1R), encoded by the CNR1 gene, and two primary endogenous ligands: 2-arachidonoylglycerol (2AG) and N-arachidonylethanolamine (AEA), hydrolyzed by monoacylglycerol lipase (gene name MGLL) and fatty
acid amide hydrolase (gene name FAAH). Preclinical data suggest that eCB/CB1R signaling acts as a stress buffer
and its loss or suppression increases depression-like behaviors. We examined circulating concentrations of the
eCBs (2-AG and AEA) days and six months after a traumatic injury as a marker of eCB/CB1R signaling and as
predictors of Center for Epidemiologic Studies of Depression Scale-Revised [CESD-R] scores as a measure of
depression severity six months after injury. We also explored associations of CNR1, FAAH, and MGLL genetic
variance with depression severity at six months. Results from hierarchical multiple linear regressions showed
that higher 2-AG serum concentrations after trauma predicted greater depression at six months (β = 0.23, p =
0.007); neither AEA after trauma, nor 2-AG and AEA at six months were significant predictors (p’s > 0.305).
Carriers of minor allele for the putative single nucleotide polymorphism in the CNR1 gene rs806371 (β = 0.19, p
= 0.024) experienced greater depression at six months. These data suggest that the eCB signaling system is highly
activated following trauma and that eCB/CB1R activity contributes to long-term depression risk.

1. Introduction
The endocannabinoid (eCB) system is a neuromodulatory system
comprised of two endogenous cannabinoid receptors, CB1R and CB2R,
and their two primary endogenous ligands, 2-arachidonoylglycerol (2AG) and N-arachidonylethanolamine (anandamide, AEA) (Hillard,
2015). The CB1R protein is encoded by the cannabinoid receptor 1
(CNR1) gene, while 2-AG and AEA are hydrolyzed by monoglyceride
lipase (MGLL) and fatty acid amide hydrolase (FAAH), respectively.
Brain eCB/CB1R signaling plays a prominent role in activity-dependent,
retrograde regulation of synaptic activity throughout the brain (Katona
and Freund, 2012) and is implicated in a number of biological systems,

including the stress system. Indeed, considerable evidence shows that
acute and chronic stress exposure alters eCB/CB1R signaling (Morena
et al., 2016). For example, glucocorticoids elevate brain 2-AG levels and
thus enhance 2AG/CB1R signaling (Hill et al., 2009), while cortico
tropin releasing hormone receptor activation increases AEA catabolism
and thus reduces AEA/CB1R signaling (Gray et al., 2015). In both cases,
the changes in eCB concentrations in the brain contribute to dampening
of endocrine and neuronal responses to stress; processing of reward;
formation, recall and extinction of aversive memories; and behavioral
responses to fear and anxiety (see (Hill et al., 2010; Lutz et al., 2015;
Morena et al., 2016) for reviews). In addition, preclinical data demon
strate that disruption of eCB/CB1R signaling causes behavioral,
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morphological and neuroendocrine changes that are associated with
human psychopathology, including anhedonia and dysregulation of the
hypothalamic-pituitary-adrenal (HPA) axis (Hillard and Liu, 2014; Lutz
et al., 2015).
In humans, eCB/CB1R signaling is also implicated in mood and
depression. The most direct evidence comes from the adverse effects of
rimonabant, a CB1 receptor antagonist, for the treatment of obesity.
Rimonabant use produces significant increases in depressive symptoms,
particularly among individuals with previous or current diagnoses of
major depression (Christensen et al., 2007; Nissen et al., 2008). In
accord with these data, administration of rimonabant has been shown to
diminish neural responses to reward in the striatum and orbitofrontal
cortex, suggesting that CB1R blockade reduces reward sensitivity, a
known feature of depression (Horder et al., 2010). Patients with major
depressive disorder (MDD) also have altered CB1R densities, with some
studies finding lower receptor densities in the anterior cingulate cortex
compared to non-depressed patients with other forms of psychopathol
ogy (e.g., schizophrenia and bipolar disorder (Choi et al., 2012; Koethe
et al., 2007)). In contrast, other postmortem investigations have found
elevated CB1R densities in the prefrontal cortex (PFC) (Hungund et al.,
2004; Vinod et al., 2005) and ventral striatum (Vinod et al., 2010) as
well as higher 2-AG concentrations (Vinod et al., 2005) in the brains of
suicide victims.
Circulating eCB concentrations, hypothesized to be biomarkers of
CNS eCB signaling (Hillard, 2018), are also altered in those with
depression. Women with MDD have lower serum 2-AG concentrations
compared to non-depressed controls (Hill et al., 2008; Hill et al., 2009)
and symptoms of depressed mood are inversely correlated with 2-AG
concentration (Hill et al., 2008; Stensson et al., 2018). On the other
hand, a recent study found significantly higher circulating concentra
tions of both AEA and 2-AG in patients with MDD, although the increase
in 2-AG did not survive correction for anti-depressant use (Romer
o-Sanchiz et al., 2019). Other studies have examined associations of
acute changes in circulating eCBs with changes in mood using exercise
(Heyman et al., 2012; Koltyn et al., 2014) and psychological stress
(Dlugos et al., 2012) to provoke acute increases in circulating 2-AG and
AEA. In healthy individuals, the increase in 2-AG – but not AEA – after
an acute exercise intervention is negatively correlated with depressed
mood (Brellenthin et al., 2017), which is in accord with the data from
depressed individuals. Similarly, a recent study found that the changes
in 2-AG and AEA concentrations evoked by exercise were positively
correlated with exercise-induced reductions in depressive symptoms in
individuals with MDD (Meyer et al., 2019). On the other hand, others
have found that circulating AEA concentrations are positively correlated
with depressive symptoms. Physically inactive, but otherwise healthy,
individuals engaging in an exercise program exhibited a reduction in
circulating AEA that was significantly associated with reduced symp
toms of mood disturbance and anger (Belitardo de Oliveira et al., 2019),
while circulating AEA concentrations in individuals with fibromyalgia
were positively correlated with symptoms of depression in another study
(Stensson et al., 2018).
In addition to altered CB1R density and circulating eCBs in depressed
individuals, CNR1, FAAH, and MGLL genotypes have been associated
with depression (Hill and Patel, 2013). Much of this research has focused
on rs1049353, a snp in the coding region of the CNR1 gene. Carriers of
the major G allele (AG/GG) at rs1049353 were more likely to exhibit
anhedonia after childhood abuse in one study (Agrawal et al., 2012),
were found to be more resistant to antidepressant treatment (Domschke
et al., 2008), and display less striatal activation to happy faces, sug
gesting reduced reward sensitivity (Chakrabarti et al., 2006). On the
other hand, other studies found that carriers of the minor A allele are
more likely to suffer from recurrent major depressive episodes (Mon
teleone et al., 2010) and do not respond as well to antidepressants
(Mitjans et al., 2012), while one study failed to find an association
(Pearson et al., 2013). Thus, while these studies support the overall
hypothesis that CB1R function contributes to risk for depression, the

directionality of the relationship is inconsistent. Other CNR1 snps have
also been associated with depression. One study found that a higher
frequency of the minor G allele at rs806371 in patients with MDD
compared to matched controls (Mitjans et al., 2013). In a large
genome-wide association study (GWAS), rs2180619 was associated with
a 4.6 times less risk for anxiety (Lazary et al., 2009), which is often
comorbid with depression (Flory and Yehuda, 2015) (although see
(Maple et al., 2016), which did not find an association between
rs2180619 genotype and depression in a small (n = 41) sample of
cannabis users). Although studied to a lesser extent FAAH and MGLL
genotypes have been linked to depression (Maple et al., 2016) and
substance abuse (Carey et al., 2015).
Based on this evidence, there has been substantial interest in
leveraging the eCB system for the treatment of depression (Chanda,
2019). Yet, our understanding of the relationship between eCB/CB1R
signaling and risk for depressive illness in humans is incomplete. In
particular, the role of eCB/CB1R signaling and risk for development of
depression following stress exposure has not yet been studied. Depres
sion is one of the most common psychiatric outcomes following trauma
(defined as a serious, life-threatening event such as a motor vehicle
crash), affecting upwards of 9% of survivors (Bryant et al., 2010) with
higher incidence (upwards of 31% when assessed six months after
trauma) in survivors of traumatic injury (Shih et al., 2010). Notably, this
rate is over four times the point prevalence of depression in the United
States general population (7.1%) (National Survey on Drug Use and
Health, 2017) and is comparable to incidence of PTSD (e.g., one study
found identical rates of PTSD and depression six months after traumatic
injury; (Shih et al., 2010). Nevertheless, investigations into the causes
for depression after trauma remain relatively rare. It is unclear what
factors predispose individuals to develop depression after trauma
(Burcusa and Iacono, 2007), but peritraumatic factors associated with
trauma have been linked to depression incidence (Ahl et al., 2017;
Joormann et al., 2020). Given the role of eCB/CB1R in stress response
and the HPA-axis, this system may also be implicated in the develop
ment of depression after trauma.
The current study investigated whether concentrations of the eCBs,
2-AG and AEA, measured in circulating blood within days of a traumatic
event were significantly related to depression severity assessed at six
months after the traumatic event. Based on the only other study to test
the relationship between endocannabinoids and prospective illness (but
not with respect to depression) (Hauer et al., 2012), we hypothesized
that greater 2-AG and AEA would predict less depression severity six
months after the traumatic event. We also explored the contributions of
genotype at CNR1 rs806371, CNR1 rs1049353, CNR1 rs2180619, FAAH
rs324420, and MGLL rs604300, hypothesizing that genetic variance in
these snps would predict depression severity at six months.
2. Materials and methods
2.1. Participants
Participants (n = 278) were recruited from a Level 1 trauma center
from a traumatically injured population and required hospitalization
after their injuries. Initially eligible participants were identified using a
trauma service census and individuals were excluded if they met any of
the following exclusion criteria: 1) younger than 18 years of age, 2)
traumatic brain injury resulting in greater than 30 min of peritraumatic
amnesia, 3) injury that resulted in an inability to communicate, 4)
Glasgow coma score of less than 13 on admission, or 5) non-English
speaking.
2.2. Study procedures
The Institutional Review Board (IRB) at the Medical College of
Wisconsin approved all study procedures and participants were mone
tarily compensated for their time. All participants completed a blood
2

J.M. Fitzgerald et al.

Neurobiology of Stress 14 (2021) 100304

draw during their hospital stay for quantification of circulating eCBs and
DNA collection. Whole blood was collected in EDTA tubes by trained
phlebotomists; this is referred to as the “post-injury” sample. A number
of demographic assessments were collected post-injury, including age,
gender, race, ethnicity, concurrent psychiatric disorders, and current use
of psychiatric medications, psychotherapy, and opiates for pain. We also
assessed via self-report whether individuals used cannabis as relation
ships between eCBs and cannabis use has been reported previously
(Morgan et al., 2013; Muhl et al., 2014; Thieme et al., 2014). Injury
characteristics were assessed via the injury severity score (ISS (Tohira
et al., 2012)). A number of clinical assessments were also collected
post-injury. Symptoms of depression were measured using the shortened
depression subscale of the Depression Anxiety and Stress Severity Scale
(DASS-21) (Osman et al., 2012). Participants also completed the PTSD
Symptom Checklist-Civilian Version (PCL-C (Weathers et al., 1994)) for
self-reported assessment of posttraumatic stress disorder (PTSD) symp
toms. When completing the PCL-C, participants were prompted to
answer questions with regard to the index traumatic injury that brought
them to the hospital.
Participants returned for a follow-up visit six months later for a blood
draw performed by trained research nursing staff for quantification of
circulating eCBs. At six months, participants completed the Clinician
Administered PTSD Scale (CAPS-5 [Weathers et al., 2018];) with respect
to the index trauma. While we relied on the self-reported DASS for the
assessment of depression at the post-injury appointment, this was done
as the recent occurrence of trauma (e.g., 3 days post) makes the clinical
assessment of the development of depression at that time suspect. This is
because the criteria for depression is defined as symptoms that occur ≥2
weeks in duration. In contrast, at six months, participants completed the
Center for Epidemiologic Studies of Depression Scale-Revised (CESD-R
(Radloff, 1977) as our main outcome measure of self-reported depres
sion. The CESD-R has high internal consistency in community (α = .94)
and clinical samples (α = .85) (Carleton et al., 2013) and is used as a
screening tool for depression based on epidemiological studies (Moon
et al., 2017). For the purposes of this study, a continuous sum score of
depression symptom severity was utilized.

2.5. Data analysis
The Hardy-Weinberg equilibrium for genotype frequencies was
assessed using chi-square tests and the R “HardyWeinberg” package
(Graffelman, 2015) with R 3.6.1 (released July 2019). Changes in eCBs
between post-injury and follow-up appointments were assessed using
repeated samples t-test.
The relationship between eCBs and CNR1, FAAH, and MGLL geno
types and depression was tested using hierarchical linear regression
(outcome = CESD-R at six months). We entered 2-AG and AEA values
post-injury and all snps in step 1 as predictors-of-interest. The following
post-injury covariates were added in step 2: age; gender; race; ethnicity;
ISS; concurrent psychiatric medication, psychotherapy, and opiate use
(in Morphine Equivalent Units [MEU]); concurrent diagnosis of psy
chiatric disorders; DASS-Depression scores post-injury; PCL-C scores
post-injury; number of days between trauma and the post-injury
appointment; time of day for the blood draw (as circulating eCBs
follow a circadian rhythm [Hanlon, 2020; Hanlon et al., 2015]); and
self-reported cannabis use. In step 3, we controlled for post-traumatic
distress severity at six months given high concordance between the
development of depression and PTSD in trauma survivors (Kessler,
1995). The CAPS-5 measures two distinct post-traumatic factors:
post-traumatic distress and general post-traumatic dysphoria (Hunt
et al., 2017); therefore, items assessing post-traumatic distress were
summed and added to the model.
Although our prior research has found relationships between eCBs,
sleep, and time since last meal (Hanlon et al., 2015; Hillard, 2018), we
found that sleep and eating habits during hospitalization in this sample
were disrupted and non-regular; thus, we did not add these as covariates
in our analysis. We report the relationship between eCBs and these
variables in Supplementary Table 1.
As values for 2-AG and AEA at the two time points (post-injury, six
months) were moderately correlated (2-AG: r(118) = 0.35, p < 0.001;
AEA: r(118) = 0.42, p < 0.001), we used a second hierarchical multiple
linear regression to examine 2-AG and AEA values obtained at six
months using a stepped approach identical to the first hierarchical linear
regression. In the second regression, concurrent psychotherapy, psy
chiatric medication, and cannabis use reflects presence of these at the six
month appointment. We again controlled for concurrent psychiatric
disorders at the six month appointment with the exception of MDD,
which was removed as it confounded the prediction of depression
severity. Opiate use at the six month appointment was not included as it
was not available. Finally, date and time of day for blood draw were
recalculated for the six month appointment. In all analyses, continuous
predictors, including time of day using a 24-h clock, were grand-mean
centered. Gender (0 = male), race (0 = White), psychiatric medication
(0 = no), psychotherapy (0 = no), concurrent psychiatric disorder (0 =
no), and cannabis use (0 = no) were dummy coded. For each snp, allele
frequency was dummy coded for carriers of the minor allele (0 = ho
mozygous major). The minor alleles are: CNR1 rs806371 (G); CNR1
rs1049353 (A), CNR1 rs2180619 (A), FAAH rs32440 (A), and MGLL
rs604300 (A). In reporting results, mean values are reported ± SD.
As our main interest in this analysis was eCBs post-injury and the
effect of CNR1 genotypes on depression, we used a Bonferronicorrection to correct against multiple corrections for the use of five
predictors (2-AG post-injury; AEA post-injury; CNR1 rs806371; CNR1
rs1049353; CNR1 rs2180619) for an α = 0.01 to consider effects
significant.

2.3. Endocannabinoid quantification
For the eCB assay, blood was collected into 2–10 ml sterile tubes (BD
Vacutainer tubes) and was allowed to clot at room temperature for a
least 30 and no more than 60 min. Samples were centrifuged using the
Beckman Coulter Allegra 6R swinging bucket centrifuge, running at
4400 RPM and at a temperature of 4 ◦ C for 20 min. Serum was pipetted
via plastic disposable 5 ml pipettes at 1.0 ml aliquots into plastic oringed cryovials (Max of 4 - 1 ml samples, if available, per draw), and
immediately frozen at − 80 ◦ C until transfer and analyses. 2-AG and AEA
in the serum were determined in lipid extracts from serum using stable
isotope dilution, liquid chromatography-mass spectrometry following
previously published methods (Crombie et al., 2018).
2.4. DNA extraction and genotyping
DNA was extracted from the 1–5 ml whole blood sample using the
Qiagen Gentra Puregene Blood Kit. The extracted DNA was rehydrated
by adding Qiagen DNA Hydration Solution and incubating the samples
in a 65 ◦ C water bath for 1 h. DNA samples were then quantified using
the Molecular Devices SpectraMax M5 spectrophotometer. Extracted
DNA (10 ng) was genotyped using ThermoFisher Scientific Taqman SNP
Genotyping Assays (CNR1: rs806371, rs1049353, rs2180619; FAAH:
rs324420; MGLL: rs604300) and Genotyping Master Mix according to
the manufacturer’s instructions. Samples were analyzed on the Quant
Studio 12K Flex Real-Time PCR instrument and genotypes manually
called using QuantStudio 12K Flex Software v.1.2.2.

3. Results
3.1. Participants
Of the 278 participants recruited, n = 172 returned for the six-month
visit, reflecting a 62% retention rate comparable to other longitudinal
investigations involving survivors of traumatic injury (e.g., 57%
3
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(Martin-Herz et al., 2012)). Participants lost to follow-up (n = 106) were
younger (37.23 ± 14.28; t(276) = 2.53, p = 0.011), but did not differ
from participants who were retained in terms of gender (χ 2(1) = 0.69, p
= 0.408), race/ethnicity (χ 2(3) = 1.67, p = 0.644), or mechanism of
injury (χ 2(9) = 12.30, p = 0.197). Those retained versus lost to follow-up
did not differ with regard to 2-AG (t(272) = 1.67, p = 0.096), AEA (t
(272) = 1.79, p = 0.075), or genotype distributions (p’s > 0.304).
The number of participants who had available genotyping and CESDR scores at six months was n = 154 for the CNR1 rs2180619 and MGLL
rs604300 snps and n = 153 for CNR1 rs806371, CNR1 rs1049353, and
FAAH rs 324420. A total of n = 153 had both CESD-R scores and
available eCBs post-injury and of these, n = 150 had both CESD-R scores
and available eCBs at six month follow-up. Outliers in 2-AG and AEA at
both visits were assessed using the outlier labeling rule of values > 2.2
SDs outside the interquartile range (Hoaglin and Iglewicz, 1987) and
subsequently removed from analysis, retaining n = 142 for the
post-injury eCB analysis and n = 140 for the six months eCB analysis. See
Table 1 for final sample demographics.

3.3. Genotype distributions
The minor allele frequencies in this sample were 0.183 for CNR1
rs806371 (G), 0.167 for CNR1 rs1049353 (A), 0.470 for CNR1
rs2180619 (A), 0.324 for FAAH rs324420 (A), and 0.158 for MGLL
rs604300 (A). Genotype distribution of all snps maintained the HardyWeinberg equilibrium (CNR1 rs806371 χ2(1) = 0.22, p = 0.636;
CNR1 rs1049353 χ2(1) = 1.04, p = 0.308; CNR1 rs2180619 χ2(1) =
0.13, p = 0.714; FAAH rs324420 χ2(1) = 1.22, p = 0.270; MGLL
rs604300 χ2(1) = 1.66, p = 0.197).
There were no gender differences with regard to genotypes (p’s >
0.328), however presence of the minor alleles for CNR1 rs1049353 (χ2
(6) = 22.30, p = 0.001), CNR1 rs2180619 (χ2(6) = 34.04, p < 0.001),
FAAH rs324420 (χ2(6) = 18.39, p = 0.005), and MGLL rs604300 (χ2(3)
= 21.45, p < 0.001) differed by race. Results from post-hoc tests
demonstrated that Whites, compared to Blacks, were more likely to
carry the minor alleles for snps CNR1 rs1049353 (χ2(2) = 15.46, p <
0.001) and MGLL rs604300 (χ2(2) = 20.12, p < 0.001). In contrast,
Blacks, compared to Whites, were more likely to carry the minor alleles
for snps CNR1 rs2180619 (χ2(2) = 23.86, p < 0.001) and FAAH
rs324420 (χ2(2) = 16.18, p < 0.001).

3.2. Depression severity post-injury and at six months
Post-injury, DASS-Depression scores ranged from 0 to 21 (3.65 ±
4.46). Using the established cut-offs, N = 110 (71%) had no depression
symptoms, N = 12 (8%) had mild depression symptoms, N = 18 (12%)
had moderate symptoms, N = 8 (5%) had severe symptoms, and N = 6
(4%) had extremely severe symptoms.
At six months, CESD-R scores ranged from 0 to 49 (14.94 ± 12.96).
Using the established cut-off of a CESD-R score of 16 (Radloff, 1977), n
= 62 (40% of the sample) met clinical criteria for MDD based on severity
of their symptoms. This rate is high compared to other published work in
trauma survivors (Shih et al., 2010; 29%).

3.4. 2-AG and AEA
Values for 2-AG and AEA concentrations in serum are depicted in
Fig. 1. Average values for 2-AG post-injury were 511.3 ng/ml (±568.2)
and 2.44 ng/ml (±0.79) for AEA. At the follow-up appointment six
months later, average values for 2-AG were 61.8 ng/ml (±45.6) and
2.33 ng/ml (±0.78) for AEA. Results from a repeated samples t-test
demonstrated a significant decline in 2-AG from post-injury to follow-up
(t(119) = 8.48, p < 0.001), but no change in AEA values between the
time points (t(118) = 0.90, p = 0.371).

Table 1
Sample demographics.

Gender (male)
Race/Ethnicity
American Indian or Alaskan Native
Black
White
Hispanic or Latino
Mechanism of injury
Motor vehicle crash
Fall
Gunshot wound
Stab wound
Motorcycle crash
Pedestrian accident
Crush injury
Recreational injury
Blunt assault
Psychiatric conditions
Major Depressive Disorder
Bipolar Disorder
Generalized Anxiety Disorder
Schizophrenia
Posttraumatic Stress Disorder
Psychiatric medications (yes)
Psychotherapy (yes)
Cannabis use (yes)
Age
Injury severity score (ISS)
Time since trauma

3.5. Post-injury eCBs and depression severity at six months
Post-injury

Six Month

Timepoint

Timepoint

N = 154

N = 140

n (%)
110 (71%)

–

2 (1%)
67 (44%)
73 (47%)
13 (8%)
49 (32%)
28 (18%)
25 (16%)
15 (10%)
14 (9%)
9 (6%)
8 (5%)
3 (2%)
3 (2%)
21 (14%)
9 (6%)
8 (5%)
6 (4%)
4 (3%)
38 (24%)
9 (6%)
47 (31%)
M (SD)
42.17 (16.37)
10.63 (6.19)
3.04 (4.99) days

For all regression analyses, distribution of eCBs were assessed for
normality and log-transformed to achieve normal distributions. Results
of our hierarchical regression testing post-injury eCBs met all assump
tions of the linear model (Table 2): errors were independent, residuals
were homoscedastic and normally distributed, and there were no
problems with multicollinearity among predictors. Step 1 of the model
that examined eCB as predictors was significant (F(7, 139) = 2.61, p =
0.015; R2 = 0.08). Greater 2-AG post-injury was associated with greater
depression severity at six months (β = 0.23, t = 2.73, p = 0.007). No
other predictors were significant using the corrected α = 0.01.
With the inclusion of covariates in step 2, the model continued to be
significant (F(26, 139) = 4.11, p < 0.001; R2 = 0.37; R2 change = 0.29)
and post-injury 2-AG continued to be a significant predictor of depres
sion at six months (β = 0.25, t = 3.24, p = 0.002).
Finally, the model continued to be significant with the inclusion of
distress symptoms at six months in step 3 (F(26, 139) = 8.43, p < 0.001;
R2 = 0.58; R2 change = 0.21), although the effect of 2-AG was now
trending (β = 0.11, t = 1.73, p = 0.088). Fig. 2 depicts partial regression
plot between log 2-AG post-injury and CESD-R scores at six months,
controlling for all covariates in Step 2.

–
–
–
–
–
–
–
–
–
–
–
–
–
–
18 (13%)
5 (4%)
3 (2%)
2 (1%)
7 (5%)
35 (25%)
16 (11%)
47 (34%)

3.6. Concurrent eCBs and depression severity at six months
Table 3 depicts results of second hierarchical linear regression.
Neither 2-AG (p = 0.306) nor AEA (p = 0.840) collected at six months
were significant predictors of depression severity in step 1. However, in
excluding the significant effect of 2-AG post-injury, carriers of the minor
allele for CNR1 rs806371 became a significant predictor of depression
symptoms in Steps 1 (β = 0.26, t = 2.89, p = 0.005) and 3 of the model
(β = 0.21, t = 2.97, p = 0.004). Fig. 3 depicts greater CESD-R at six
months for carriers of the minor allele for CNR1 rs806371.

–
–
6.33 (0.69) months

Note. M = mean; SD = standard deviation. Concurrent psychiatric conditions are
not mutually exclusive. ISS provides a clinical estimate of the severity of a
traumatic injury to the body.
4
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Fig. 1. Values for endocannabinoids 2-arachidonylglycerol (2-AG) (Panel A) and anandamide (AEA) (Panel B) post-injury and at six months. Error bars reflect
±standard error of the mean. ***p < 0.001.

Given the significant effect for CNR1 rs806371, we also examined in
follow-up tests whether there was a dosing effect by genotype on
depression severity (G/G > G/T > T/T) using an ANCOVA, including
covariates used in the regression. Pairwise comparisons showed that
homozygous T/T had less depression than heterozygous G/T (p =
0.020), but that G/T did not differ from homozygous G/G (p = 0.587).

distress would reduce the impact of stress on the brain and, thus, the risk
to develop chronic depression. Indeed, a far smaller study (n = 16) found
that depression at six months following cardiac surgery was greater in
patients with the lowest circulating 2-AG concentrations at the time of
surgery (Hauer et al., 2012). By contrast, we provide evidence that
higher circulating concentrations of 2-AG in the days after trauma pre
dicts greater depressive symptoms six months later. One explanation for
these results is that both a large increase in 2-AG and risk for depression
are consequences of the very significant physical and psychological
stress that accompanied the traumatic injuries to our sample and that
2-AG and risk for depression are not directly, causally related. A more
plausible explanation based upon evidence that 2-AG/CB1R signaling is
mechanistically linked to protection from stress, is that the large in
crease in 2-AG induced by the stress down-regulates CB1R signaling.
This is consistent with evidence from preclinical studies that high brain
concentrations of 2-AG are associated with reduced CB1R binding site
density, likely as a result of agonist-induced desensitization and receptor
down-regulation (Schlosburg et al., 2010). Thus, sustained elevated
2-AG concentrations as a consequence of the severe traumatic injury
could perhaps reduce rather than enhance 2-AG/CB1R signaling. To
note, the effect of 2-AG was only trending when controlling for
distress-specific symptoms at six months, suggesting that while elevated
2-AG is significantly associated with depression, it is also associated
with general distress symptoms of PTSD.
We did not find any relationship between concurrent measures of
circulating eCBs and depression at six months. This finding is also at
odds with prior studies finding diminished circulating 2-AG in in
dividuals with established, chronic depression (Hill et al., 2008, 2009b).
However, an earlier study found that circulating 2-AG concentrations
were inversely related to the length of the depressive episode, with the
data in that report showing that reductions in 2-AG were not pro
nounced at 26 weeks, which is the time frame of our study (Hill et al.,
2008). Thus, concentrations of circulating 2-AG may be a particular
feature of depression chronicity. An untested hypothesis is that circu
lating 2-AG concentrations would continue to fall in the individuals with
depression in our study population. Encouraging evidence for this the
ory is the fact that we found greater decline in 2-AG over time in in
dividuals with greater depression severity, suggesting that change in
levels were meaningfully related to depression. More studies focused on
the time course of changes (over days and months) in circulating eCBs
after stress will help clarify these questions.
The lack of relationship between concurrent measures of circulating
AEA concentrations and symptoms of depression at six months is in
agreement with some (Hill et al., 2008) but not all (Hill et al., 2009a,b)
previous studies. In one study, AEA concentrations were significantly
elevated in women with minor depression and significantly negatively
correlated with symptoms of anxiety, rather than depression (Hill et al.,
2008). In rodents, Eisenstein and colleagues found reduced 2-AG and
AEA content in the brains of OBX animals, which induces a depression
phenotype, but only a direct correlation between 2-AG levels and
depressive behaviors (Eisenstein et al., 2010). Other work similarly
shows only alterations in brain 2-AG levels in preclinical models of

3.7. Change in eCBs and depression severity at six months
In exploratory analyses we also examined whether change in eCBs
between the post-injury and the six month appointment was related to
depression severity at six months. Change scores were calculated sub
tracting eCB values at six months from eCB values post-injury, with
positive values indicating less decline over time. We found that
depression severity at six months was negatively associated with change
in 2-AG (r(118) = − 0.30, p = 0.001), suggesting that more decline in 2AG over time was related to more depression severity at six months.
Supplemental Fig. 1 shows the relationship between change in 2-AG and
depression severity at six months. In contrast, we found no relationship
between change in AEA and depression symptoms at six months (r(118)
= 0.04, p = 0.640).
4. Discussion
This investigation examined circulating concentrations of the eCBs,
2-AG and AEA, along with CNR1, FAAH, and MGLL polymorphisms as
predictors of depression severity six months after a traumatic injury. We
found that higher concentrations of 2-AG post-injury, collected an
average of 3 days after injury, was a significant predictor of greater
depression severity six months later. We also found that genotype CNR1
rs806371 was a significant predictor of depression severity at six
months, such that individuals with one or more copies of the rare allele
(G/G or G/A) experienced more depression. We did not find evidence
that post-injury circulating AEA concentrations predict risk for devel
opment of depression in this study, nor that concurrent circulating
concentrations of 2-AG or AEA were associated with severity of
depression at six months.
The subjects in this study were exposed to a range of injury types;
while injury severity was variable, all of the subjects required hospi
talization. The circulating concentrations of 2-AG were very high in this
population, about 100 fold higher than reported in other studies (Hillard
et al., 2012). Interestingly, a study of circulating eCBs in patients un
dergoing cardiac surgery with cardiopulmonary bypass, a very invasive
procedure, also found a large increase in circulating concentrations of
2-AG (112 ng/ml before to 321 ng/ml after the procedure) (Weis et al.,
2010). Together with other studies showing more moderate increases in
circulating 2-AG concentrations following less severe stress (Hillard
et al., 2016), this suggests that 2-AG in the circulation is sensitive to the
degree of stress or distress imposed upon the individual.
As discussed above, preclinical studies suggest that activation of the
eCB system buffers the stress response, and the diathesis stress model
predicts that a high 2-AG concentration at the time of acute stress/
5
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Table 2
Hierarchical linear regression testing endocannabinoids collected at post-injury.
CESD-R
Variable
Step 1
Intercept
2-AG at post-injury
AEA at post-injury
CNR1 rs806371 (0 = T/T)
CNR1 rs1049353 (0 = G/G)
CNR1 rs2180619 (0 = G/G)
FAAH rs324420 (0 = C/C)
MGLL rs604300 (0 = G/G)
Step 2
Intercept
2-AG at post-injury
AEA at post-injury
CNR1 rs806371 (0 = T/T)
CNR1 rs1049353 (0 = G/G)
CNR1 rs2180619 (0 = G/G)
FAAH rs324420 (0 = C/C)
MGLL rs604300 (0 = G/G)
DASS-Depression at post-injury
PCL-C at post-injury
Psychotherapy at post-injury (0 = no)
Psychiatric medication at post-injury (0 = no)
Psychiatric diagnosis at post-injury: MDD (0 = no)
Psychiatric diagnosis at post-injury: GAD (0 = no)
Psychiatric diagnosis at post-injury: PTSD (0 = no)
Psychiatric diagnosis at post-injury: BD (0 = no)
Psychiatric diagnosis at post-injury: Schizophrenia (0 = no)
MEU
Marijuana use at post-injury (0 = no)
ISS
Days since trauma at post-injury
Time of blood draw at post-injury
Gender (0 = male)
Age
Race (American Indian or Alaskan Native [0 = White])
Race (Black [0 = White])
Ethnicity (0 = Non-Hispanic or Latino)
Step 3
Intercept
2-AG at post-injury
AEA at post-injury
CNR1 rs806371 (0 = T/T)
CNR1 rs1049353 (0 = G/G)
CNR1 rs2180619 (0 = G/G)
FAAH rs324420 (0 = C/C)
MGLL rs604300 (0 = G/G)
DASS-Depression at post-injury
Psychotherapy at post-injury (0 = no)
Psychiatric medication at post-injury (0 = no)
Psychiatric diagnosis at post-injury: MDD (0 = no)
Psychiatric diagnosis at post-injury: GAD (0 = no)
Psychiatric diagnosis at post-injury: PTSD (0 = no)
Psychiatric diagnosis at post-injury: BD (0 = no)
Psychiatric diagnosis at post-injury: Schizophrenia (0 = no)
MEU
Marijuana use at post-injury (0 = no)
ISS
Days since trauma at post-injury
Time of blood draw at post-injury
Gender (0 = male)
Age
Race (American Indian or Alaskan Native [0 = White])
Race (Black [0 = White])
Ethnicity (0 = Non-Hispanic or Latino)
CAPS Distress at six months

B

SE

β

t

p-value

10.173
5.11
0.21
5.40
1.09
2.00
3.17
− 3.29

2.729
1.87
8.08
2.36
2.43
2.43
2.22
2.82

0.23
0.00
0.19
0.04
0.07
0.12
− 0.10

3.727
2.73
0.03
2.29
0.45
0.83
1.43
− 1.17

<0.001***
0.007**
0.979
0.024*
0.653
0.411
0.155
0.245

2.59
5.53
8.11
4.92
4.55
4.30
0.64
4.44
0.77
0.19
1.15
6.69
− 3.80
− 5.18
3.46
− 12.08
− 7.90
0.00
0.93
− 0.12
0.08
0.11
1.43
− 0.05
10.19
7.81
9.53

3.23
1.71
7.74
2.14
2.33
2.20
2.03
2.77
0.29
0.08
4.45
5.16
5.98
5.63
7.05
6.18
6.59
0.00
2.30
0.16
0.20
0.76
2.55
0.07
8.89
2.60
3.94

0.25
0.09
0.18
0.15
0.15
0.02
0.13
0.26
0.24
0.02
0.22
− 0.09
− 0.09
0.04
− 0.23
− 0.12
− 0.03
0.03
− 0.06
0.03
0.01
0.05
− 0.07
0.09
0.30
0.20

0.80
3.24
1.05
2.30
1.96
1.96
0.31
1.60
2.72
2.45
0.26
1.30
− 0.64
− 0.92
0.49
− 1.96
− 1.20
− 0.45
0.40
− 0.76
0.39
0.14
0.56
− 0.73
1.15
3.00
2.42

0.423
0.002**
0.297
0.024*
0.053
0.052
0.754
0.112
0.008**
0.016*
0.796
0.198
0.527
0.360
0.625
0.053
0.233
0.656
0.687
0.450
0.701
0.889
0.577
0.469
0.254
0.003**
0.017*

8.12
2.48
2.28
4.49
2.32
2.64
0.59
2.61
0.99
0.49
4.47
− 0.36
− 2.63
2.19
− 10.00
− 7.48
0.00
1.88
− 0.14
− 0.06
0.00
− 0.51
0.01
2.67
1.53
5.30
0.82

2.73
1.44
6.23
1.75
1.91
1.80
1.64
2.26
0.20
3.55
4.22
4.83
4.60
5.75
5.05
5.24
0.00
1.87
0.13
0.17
0.62
2.09
0.06
7.28
2.28
3.26
0.10

0.11
0.02
0.16
0.08
0.09
0.02
0.08
0.34
0.01
0.15
− 0.01
− 0.04
0.02
− 0.19
− 0.12
0.01
0.07
− 0.07
− 0.02
0.00
− 0.02
0.01
0.02
0.06
0.11
0.57

2.97
1.72
0.37
2.57
1.21
1.47
0.36
1.16
4.97
0.14
1.06
− 0.07
− 0.57
0.38
− 1.98
− 1.43
0.19
1.00
− 1.06
− 0.34
0.00
− 0.25
0.20
0.37
0.67
1.62
8.10

0.004**
0.088
0.715
0.012*
0.227
0.146
0.721
0.250
<0.001***
0.891
0.292
0.941
0.569
0.703
0.050
0.156
0.851
0.318
0.291
0.734
0.999
0.806
0.846
0.715
0.504
0.107
<0.001***

Note. CESD-R = Center for Epidemiologic Studies of Depression Scale-Revised; 2-AG = 2-arachidonoyl Glycerol; AEA = Anandamide; CNR1 = Cannabinoid Receptor 1;
FAAH = Fatty Acid Amide Hydrolase; MGLL = Monoglyceride Lipase; DASS = Depression Anxiety and Stress Scale; PCL-C = PTSD Checklist-Civilian Version; MDD =
Major Depressive Disorder; GAD = Generalized Anxiety Disorder; PTSD = Posttraumatic Stress Disorder; BD = Bipolar Disorder; MEU = morphine equivalent units;
ISS = injury severity score; CAPS = Clinician Administered PTSD Scale. ***p < 0.001, **p < 0.01, *p < 0.05.
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(Chakrabarti et al., 2006), supporting the hypothesis that CNR1 geno
type affects brain function. A study in 217 Whites found more carriers of
the minor allele (A) at rs1049353 among MDD patients than healthy
controls, suggesting that the minor allele increases risk for depression
(Monteleone et al., 2010). Additionally, the major allele at this position
(G) is part of a haplotype associated with protection from depression
(Mitjans et al., 2013), while, in males only, GG carriers exhibited a
marginally improved therapeutic response to citalopram (Mitjans et al.,
2012). On the other hand, a study of more than 250 patients with MDD
found that the major (G) allele was associated with increased risk for
antidepressant treatment resistance and hypo-responsiveness of
subcortical regions to social reward stimuli (Domschke et al., 2008).
Similarly, a study that investigated two large (<1000) data sets found
that carriers of the A allele were protected against the effect of childhood
physical abuse to induce anhedonia as adults (Agrawal et al., 2012).
However, another study asked a similar question and found no associ
ation between depression and genetic variability at rs1049535 (Pearson
et al., 2013). Given that several of these effects were small in size or were
obtained from small sample size studies (n = 19 to 41), it is possible that
the statistical significance is spurious. It is also possible that differences
in results may be attributed to specific associations between the major
allele and depression symptoms (anhedonia for example [Agrawal et al.,
2012]) or assessment of the presence of depression as a lifetime diag
nosis, rather than current symptoms of the disorder (Pearson et al.,
2013). Thus, differences in direction of effects may be driven by
sub-components of depression rather than global symptoms. Finally,
differences in results may be driven by racial diversity. Our study is
racially diverse with approximately half (53%) of our sample classified
as racial minorities. In addition, we found differences in the distribution
of minor alleles at CNR1 rs1049535 and rs2180619 by race, suggesting
that differences in effects between studies may be attributed to distri
bution of minor vs. major alleles in these samples.
The present study is not without limitations. First, although in
dividuals that were lost to follow-up over the course of this study did not
differ in post-injury eCB measures, sample size was reduced and effects
of drop-out cannot be tested, particularly the question of whether these
individuals experienced different levels of depression. Second, we did
not measure eCB concentrations at interim months between the acute
period and six months to adequately capture a slope of descending eCBs
that may be meaningfully tied to depression risk. Third, a self-reported
measure of depression was used and effects should be tested against
clinician-assessed depression outcomes. Fourth, our prior research
shows that eCBs can be influenced by exercise, although change in eCBs
following exercise is attenuated in those with psychiatric illness
(Crombie et al., 2018). Nevertheless, the effects of exercise was not a
focus of this research and was therefore not controlled for in this anal
ysis. Finally, there was variability in the time between blood draws and
serum harvest. Although variability in these times (30–60 min) was
entirely random, we cannot rule out the possibility that variation could
theoretically account for relationships seen in the study.
Even with the limitations the clinical implications of this study are
worth mentioning. Despite the suggestion that eCBs provide a potential
novel therapeutic for psychopathology (Chanda, 2019), our data sug
gests that augmenting eCBs may not be clinically advised in some cases.
The data here suggest that timing matters greatly if the field moves to
wards augmenting eCBs for the treatment of mental illness. In particular,
these finding suggest that eCB/CB1R-related interventions immediately
after trauma should consider the possibility that CNS eCB concentrations
may be abnormally elevated by the trauma, to the point that 2-AG/CB1R
signaling is at a ceiling. Therefore, interventions to increase eCB con
centrations further (particularly 2-AG) could increase risk for psycho
pathology. Instead, this research suggests that alternative treatments,
such as administration of a DAGL inhibitor shortly after trauma to
inhibit 2-AG formation, may be most beneficial to reduce depression six
months later. Because of these nuances, more research is needed spe
cifically to unmask the biological processes that underlie elevated eCBs

Fig. 2. Partial regression plot showing relationship between 2-arachidonylgly
cerol (2-AG) post-injury and depression severity at six months measured by
CESD-R (Center for Epidemiologic Studies of Depression Scale-Revised). Rela
tionship controls for all demographic covariates in Step 2 (β = 0.25, t = 3.24, p
= 0.002).

depression, with no evidence for altered AEA (Bortolato et al., 2007; M.
N. Hill et al., 2005; Sciolino et al., 2011). Together, these data suggest
that 2-AG and AEA may be differentially associated with symptoms of
mental illness.
We found that genotype at CNR1 rs806371, a snp in the promoter
region of CNR1, significantly contributed to risk for depression and that
carriers of the minor allele (G) at rs806371 had greater depression
severity at six months after injury. This finding is in accord with the
results of an earlier study in more than 300 individuals with MDD in
which the minor allele at this locus was significantly associated with
melancholic (p = 0.04) and psychotic (p = 0.004) symptoms (Mitjans
et al., 2013). Wilke and colleagues identified the same snp in a study of
the impact of CNR1 genotype on cholesterol homeostasis and demon
strated that rs806371 is a functional allele within the CNR1 promoter
(Feng et al., 2013). Importantly, they discovered, using electrophoretic
mobility shift assays, that the presence of G, but not the major allele T, at
rs806371 creates a novel regulatory binding element in the promoter.
Furthermore, reporter assays demonstrated that reporter gene expres
sion was significantly reduced when the nucleotide at rs806371 was G.
Thus, these data indicate the minor allele at this site, which is associated
with increased depression severity in our study, likely reduces CB1R
expression. These data support the general hypothesis that CB1R
signaling regulates mood and, more specifically, that reduced CB1R
signaling, in this case as a result of reduced expression, contributes to
increased risk for depression following trauma.
The other CNR1 alleles we studied had trending effects that did not
survive correction for PTSD distress symptoms, suggesting that they do
not confer risk for depression per se. In agreement with that hypothesis,
earlier studies have provided strong support for the role of genotype at
rs2180619 in trait anxiety (Lazary et al., 2009), fear extinction (Heitland
et al., 2012), sleep quality (Maple et al., 2016), and affective working
memory (Fairfield et al., 2018). All of these processes are important
contributors to the symptoms of PTSD (Colvonen et al., 2019). In
addition, we also did not find evidence that FAAH and MGLL snps were
associated with depression, which partly contradicts prior work. For
instance, Maple and colleagues found that C/C carriers of FAAH
rs324420 had greater depressive symptoms in a small sample (n = 41)
(Maple et al., 2016). We are presently unaware of any study linking
MGLL genetic variation to depression, though its involvement in hy
drolyzing 2-AG and association with comorbid conditions such as sub
stance abuse provided impetus in this study.
In contrast, previous studies have identified associations between
rs1049353 and mood, although the results have been mixed. An early
imaging genetics study in less than 20 individuals found that genotype at
this snp was associated with activation of striatal regions by happy faces
7
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Table 3
Hierarchical linear regression testing endocannabinoids collected at six months.
CESD-R
Variable
Step 1
Intercept
2-AG at six months
AEA at six months
CNR1 rs806371 (0 = T/T)
CNR1 rs1049353 (0 = G/G)
CNR1 rs2180619 (0 = G/G)
FAAH rs324420 (0 = C/C)
MGLL rs604300 (0 = G/G)
Step 2
Intercept
2-AG at six months
AEA at six months
CNR1 rs806371 (0 = T/T)
CNR1 rs1049353 (0 = G/G)
CNR1 rs2180619 (0 = G/G)
FAAH rs324420 (0 = C/C)
MGLL rs604300 (0 = G/G)
Psychotherapy at six months (0 = no)
Psychiatric medication at six months (0 = no)
Psychiatric diagnosis at six months: GAD (0 = no)
Psychiatric diagnosis at six months: PTSD (0 = no)
Psychiatric diagnosis at six months: BD (0 = no)
Psychiatric diagnosis at six months: Schizophrenia (0 = no)
Marijuana use at six months (0 = no)
ISS
Days since trauma at six months
Time of blood draw at six months
Gender (0 = male)
Age
Race (American Indian or Alaskan Native [0 = White])
Race (Black [0 = White])
Ethnicity (0 = Non-Hispanic or Latino)
Step 3
Intercept
2-AG at six months
AEA at six months
CNR1 rs806371 (0 = T/T)
CNR1 rs1049353 (0 = G/G)
CNR1 rs2180619 (0 = G/G)
FAAH rs324420 (0 = C/C)
MGLL rs604300 (0 = G/G)
Psychotherapy at six months (0 = no)
Psychiatric medication at six months (0 = no)
Psychiatric diagnosis at six months: GAD (0 = no)
Psychiatric diagnosis at six months: PTSD (0 = no)
Psychiatric diagnosis at six months: BD (0 = no)
Psychiatric diagnosis at six months: Schizophrenia (0 = no)
Marijuana use at six months (0 = no)
ISS
Days since trauma at six months
Time of blood draw at six months
Gender (0 = male)
Age
Race (American Indian or Alaskan Native [0 = White])
Race (Black [0 = White])
Ethnicity (0 = Non-Hispanic or Latino)
CAPS Distress at six months

B

SE

β

t

p-value

7.944
− 4.07
− 1.69
7.38
5.18
3.58
5.22
− 4.51

3.03
3.95
8.38
2.56
2.72
2.63
2.44
2.99

− 0.09
− 0.02
0.26
0.17
0.12
0.19
− 0.14

2.62
− 1.03
− 0.20
2.89
1.91
1.36
2.14
− 1.51

0.010*
0.306
0.840
0.005**
0.059
0.175
0.034*
0.134

− 0.77
− 2.07
1.60
6.90
6.39
3.51
3.95
1.20
4.75
6.59
− 2.69
2.53
− 9.55
− 11.69
0.42
− 0.15
0.14
− 0.05
2.62
− 0.10
9.35
9.91
2.88

3.90
4.09
8.20
2.62
2.75
2.64
2.42
3.17
4.04
3.59
7.99
5.51
7.22
9.91
2.72
0.20
0.06
0.56
2.77
0.09
9.92
3.24
4.90

− 0.05
0.02
0.24
0.21
0.12
0.15
0.04
0.12
0.21
− 0.03
0.04
− 0.13
− 0.11
0.02
− 0.07
0.22
− 0.01
0.09
− 0.12
0.09
0.37
0.06

− 0.20
− 0.51
0.20
2.64
2.32
1.33
1.63
0.38
1.17
1.84
− 0.34
0.46
− 1.32
− 1.18
0.15
− 0.75
2.50
− 0.09
0.95
− 1.08
0.94
3.06
0.59

0.844
0.613
0.846
0.010*
0.022*
0.186
0.106
0.707
0.243
0.069
0.737
0.647
0.189
0.241
0.879
0.456
0.014*
0.926
0.346
0.281
0.348
0.003**
0.558

11.18
− 3.56
− 1.97
6.06
1.54
− 0.09
0.62
1.22
− 0.64
8.04
− 1.69
− 6.68
− 12.91
− 21.42
− 0.99
− 0.16
0.09
0.28
− 0.70
0.03
7.02
0.53
− 2.19
0.48

3.13
2.99
6.01
1.92
2.08
1.97
1.81
2.32
3.01
2.63
5.85
4.15
5.29
7.32
1.99
0.15
0.04
0.41
2.05
0.07
7.26
2.58
3.63
0.05

− 0.08
− 0.02
0.21
0.05
0.00
0.02
0.04
− 0.02
0.26
− 0.02
− 0.12
− 0.17
− 0.20
− 0.03
− 0.07
0.15
0.05
− 0.02
0.03
0.07
0.02
− 0.05
0.76

3.569
− 1.19
− 0.33
3.16
0.74
− 0.05
0.34
0.52
− 0.21
3.06
− 0.29
− 1.61
− 2.44
− 2.93
− 0.50
− 1.12
2.25
0.69
− 0.34
0.42
0.97
0.21
− 0.60
9.25

0.001**
0.238
0.743
0.002**
0.460
0.964
0.733
0.602
0.833
0.003**
0.773
0.111
0.017
0.004**
0.622
0.265
0.026
0.491
0.736
0.674
0.336
0.837
0.548
<0.001***

Note. CESD-R = Center for Epidemiologic Studies of Depression Scale-Revised; 2-AG = 2-arachidonoyl Glycerol; AEA = Anandamide; CNR1 = Cannabinoid Receptor 1;
FAAH = Fatty Acid Amide Hydrolase; MGLL = Monoglyceride Lipase; DASS = Depression Anxiety and Stress Scale; MDD = Major Depressive Disorder; GAD =
Generalized Anxiety Disorder; PTSD = Posttraumatic Stress Disorder; BD = Bipolar Disorder; MEU = morphine equivalent units; ISS = injury severity score; CAPS =
Clinician Administered PTSD Scale. ***p < 0.001, **p < 0.01, *p < 0.05.

and the mechanism(s) by which elevated eCB concentrations contribute
to risk for depression. An additional future direction of this research is to
examine the mechanisms of the relationship between serum eCBs and
brain signaling that is known to underlie the presentation of depression.
The current study is the first to link circulating concentrations of

eCBs acutely after trauma to long-term depression outcomes. In previous
work we found that elevated AEA (but not 2-AG) after injury was a
prospective predictor of PTSD severity six months after trauma (deR
oon-Cassini and Hillard, 2016) and that AEA correlated with somatic
anxiety symptoms in individuals who are depressed (Hill et al., 2008).
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the eCB system may also be important for dissociating specific risk for
depression in this population.
Funding
This work was supported by the National Institute of Mental Health
(NIMH R21 MH102838; deRoon-Cassini, Hillard). This funding source
had no direct involvement in the design, collection, analysis, and writing
of this report. Drs. Fitzgerald, Chesney, Brasel, and Larson have no
financial disclosures to report.
CRediT authorship contribution statement
Jacklynn M. Fitzgerald: Formal analysis, Methodology, Visualiza
tion, writing. Samantha A. Chesney: formal analyses, review and
editing. Tara Sander Lee: Data curation, Investigation, Methodology.
Karen Brasel: Conceptualization, review and editing. Christine L.
Larson: Supervision, review and editing. Cecilia J. Hillard: Concep
tualization, Methodology, Supervision, review and editing. Terri A.
deRoon-Cassini: Conceptualization, Methodology, Supervision, review
and editing.
Declaration of competing interest
This work was supported by the National Institute of Mental Health
(NIMH R21 MH102838; deRoon-Cassini, Hillard). This funding source
had no direct involvement in the design, collection, analysis, and writing
of this report. Drs. Fitzgerald, Chesney, Brasel, and Larson have no
financial disclosures to report and no authors have any conflicts of in
terest to report.
Appendix A. Supplementary data
Supplementary data to this article can be found online at https://doi.
org/10.1016/j.ynstr.2021.100304.
References
Agrawal, A., Nelson, E.C., Littlefield, A.K., Bucholz, K.K., Degenhardt, L., Henders, A.K.,
Madden, P.A.F., Martin, N.G., Montgomery, G.W., Pergadia, M.L., Sher, K.J.,
Heath, A.C., Lynskey, M.T., 2012. Cannabinoid receptor genotype moderation of the
effects of childhood physical abuse on anhedonia and depression. Arch. Gen.
Psychiatr. 69 (7) https://doi.org/10.1001/archgenpsychiatry.2011.2273.
Ahl, R., Lindgren, R., Cao, Y., Riddez, L., Mohseni, S., 2017. Risk factors for depression
following traumatic injury: an epidemiological study from a scandinavian trauma
center. Injury 48 (5), 1082–1087. https://doi.org/10.1016/j.injury.2017.03.019.

9

J.M. Fitzgerald et al.

Neurobiology of Stress 14 (2021) 100304

Hauer, D., Weis, F., Campolongo, P., Schopp, M., Beiras-Fernandez, A., Strewe, C.,
Giehl, M., Toth, R., Kilger, E., Schelling, G., 2012. Glucocorticoid-endocannabinoid
interaction in cardiac surgical patients: relationship to early cognitive dysfunction
and late depression. Rev. Neurosci. 23 (5–6) https://doi.org/10.1515/revneuro2012-0058.
Heitland, I., Klumpers, F., Oosting, R.S., Evers, D.J.J., Leon Kenemans, J., Baas, J.M.P.,
2012. Failure to extinguish fear and genetic variability in the human cannabinoid
receptor 1. Transl. Psychiatry 2 (9), e162. https://doi.org/10.1038/tp.2012.90.
Heyman, E., Gamelin, F.-X., Aucouturier, J., Di Marzo, V., 2012. The role of the
endocannabinoid system in skeletal muscle and metabolic adaptations to exercise:
potential implications for the treatment of obesity: exercise and the
endocannabinoid system. Obes. Rev. 13 (12), 1110–1124. https://doi.org/10.1111/
j.1467-789X.2012.01026.x.
Hill, M., Miller, G., Ho, W.-S., Gorzalka, B., Hillard, C., 2008. Serum endocannabinoid
content is altered in females with depressive disorders: a preliminary report.
Pharmacopsychiatry 41 (2), 48–53. https://doi.org/10.1055/s-2007-993211.
Hill, M.N., McLaughlin, R.J., Bingham, B., Shrestha, L., Lee, T.T.Y., Gray, J.M., Hillard, C.
J., Gorzalka, B.B., Viau, V., 2010. Endogenous cannabinoid signaling is essential for
stress adaptation. Proc. Natl. Acad. Sci. Unit. States Am. 107 (20), 9406–9411.
https://doi.org/10.1073/pnas.0914661107.
Hill, Matthew N., Patel, S., 2013. Translational evidence for the involvement of the
endocannabinoid system in stress-related psychiatric illnesses. Biol. Mood Anxiety
Disord. 3 (1), 19.
Hill, M.N., McLaughlin, R.J., Morrish, A.C., Viau, V., Floresco, S.B., Hillard, C.J.,
Gorzalka, B.B., 2009a. Suppression of amygdalar endocannabinoid signaling by
stress contributes to activation of the hypothalamic–pituitary–adrenal Axis.
Neuropsychopharmacology 34 (13), 2733–2745. https://doi.org/10.1038/
npp.2009.114.
Hill, M.N., Miller, G.E., Carrier, E.J., Gorzalka, B.B., Hillard, C.J., 2009b. Circulating
endocannabinoids and N-acyl ethanolamines are differentially regulated in major
depression and following exposure to social stress. Psychoneuroendocrinology 34
(8), 1257–1262. https://doi.org/10.1016/j.psyneuen.2009.03.013.
Hill, M.N., Patel, S., Carrier, E.J., Rademacher, D.J., Ormerod, B.K., Hillard, C.J.,
Gorzalka, B.B., 2005. Downregulation of endocannabinoid signaling in the
Hippocampus following chronic unpredictable stress. Neuropsychopharmacology 30
(3), 508–515. https://doi.org/10.1038/sj.npp.1300601.
Hillard, C., Liu, Q., 2014. Endocannabinoid signaling in the etiology and treatment of
major depressive illness. Curr. Pharmaceut. Des. 20 (23), 3795–3811. https://doi.
org/10.2174/13816128113196660735.
Hillard, Cecilia J., 2015. The endocannabinoid signaling system in the CNS. Int. Rev.
Neurobiol. 125, 1–47. https://doi.org/10.1016/bs.irn.2015.10.001. Elsevier.
Hillard, C.J., 2018. Circulating endocannabinoids: from whence do they come and where
are they going? Neuropsychopharmacology 43 (1), 155–172. https://doi.org/
10.1038/npp.2017.130.
Hillard, C.J., Beatka, M., Sarvaideo, J., 2016. Endocannabinoid signaling and the
hypothalamic-pituitary-adrenal Axis. In: Terjung, R. (Ed.), Comprehensive
Physiology. John Wiley & Sons, Inc, pp. 1–15. https://doi.org/10.1002/cphy.
c160005.
Hillard, C.J., Weinlander, K.M., Stuhr, K.L., 2012. Contributions of endocannabinoid
signaling to psychiatric disorders in humans: genetic and biochemical evidence.
Neuroscience 204, 207–229. https://doi.org/10.1016/j.neuroscience.2011.11.020.
Hoaglin, D.C., Iglewicz, B., 1987. Fine-tuning some resistant rules for outlier labeling.
J. Am. Stat. Assoc. 82 (400), 1147–1149.
Horder, J., Harmer, C.J., Cowen, P.J., McCabe, C., 2010. Reduced neural response to
reward following 7 days treatment with the cannabinoid CB1 antagonist rimonabant
in healthy volunteers. Int. J. Neuropsychopharmacol. 13 (8), 1103–1113. https://
doi.org/10.1017/S1461145710000453.
Hungund, B.L., Vinod, K.Y., Kassir, S.A., Basavarajappa, B.S., Yalamanchili, R.,
Cooper, T.B., Mann, J.J., Arango, V., 2004. Upregulation of CB1 receptors and
agonist-stimulated [35S]GTPγS binding in the prefrontal cortex of depressed suicide
victims. Mol. Psychiatr. 9 (2), 184–190. https://doi.org/10.1038/sj.mp.4001376.
Hunt, J.C., Chesney, S.A., Jorgensen, T.D., Schumann, N.R., deRoon-Cassini, T.A., 2017.
Exploring the gold-standard: evidence for a two-factor model of the clinician
administered PTSD Scale for the DSM–5. Psychological Trauma: Theory, Research,
Practice, and Policy. https://doi.org/10.1037/tra0000310.
Joormann, J., McLean, S.A., Beaudoin, F.L., An, X., Stevens, J.S., Zeng, D., Neylan, T.C.,
Clifford, G., Linnstaedt, S.D., Germine, L.T., Rauch, S.L., Musey, P.I., Hendry, P.L.,
Sheikh, S., Jones, C.W., Punches, B.E., Fermann, G., Hudak, L.A., Mohiuddin, K.,
Kessler, R.C., 2020. Socio-demographic and trauma-related predictors of depression
within eight weeks of motor vehicle collision in the AURORA study. Psychol. Med.
1–14. https://doi.org/10.1017/S0033291720003773.
Katona, I., Freund, T.F., 2012. Multiple functions of endocannabinoid signaling in the
brain. Annu. Rev. Neurosci. 35 (1), 529–558. https://doi.org/10.1146/annurevneuro-062111-150420.
Kessler, R.C., 1995. Posttraumatic stress disorder in the national comorbidity Survey.
Arch. Gen. Psychiatr. 52 (12), 1048. https://doi.org/10.1001/
archpsyc.1995.03950240066012.
Koethe, D., Llenos, I.C., Dulay, J.R., Hoyer, C., Torrey, E.F., Leweke, F.M., Weis, S., 2007.
Expression of CB1 cannabinoid receptor in the anterior cingulate cortex in
schizophrenia, bipolar disorder, and major depression. J. Neural. Transm. 114 (8),
1055–1063. https://doi.org/10.1007/s00702-007-0660-5.
Koltyn, K.F., Brellenthin, A.G., Cook, D.B., Sehgal, N., Hillard, C., 2014. Mechanisms of
exercise-induced hypoalgesia. J. Pain 15 (12), 1294–1304. https://doi.org/10.1016/
j.jpain.2014.09.006.
Lazary, J., Lazary, A., Gonda, X., Benko, A., Molnar, E., Hunyady, L., Juhasz, G.,
Bagdy, G., 2009. Promoter variants of the cannabinoid receptor 1 gene (CNR1) in

interaction with 5-HTTLPR affect the anxious phenotype. Am. J. Med. Genet. Part B:
Neuropsychiatric Genetics 150B (8), 1118–1127. https://doi.org/10.1002/ajmg.
b.31024.
Lutz, B., Marsicano, G., Maldonado, R., Hillard, C.J., 2015. The endocannabinoid system
in guarding against fear, anxiety and stress. Nat. Rev. Neurosci. 16 (12), 705–718.
https://doi.org/10.1038/nrn4036.
Maple, K.E., McDaniel, K.A., Shollenbarger, S.G., Lisdahl, K.M., 2016. Dose-dependent
cannabis use, depressive symptoms, and FAAH genotype predict sleep quality in
emerging adults: a pilot study. Am. J. Drug Alcohol Abuse 42 (4), 431–440. https://
doi.org/10.3109/00952990.2016.1141913.
Martin-Herz, S.P., Zatzick, D.F., McMahon, R.J., 2012. Health-related quality of life in
children and adolescents following traumatic injury: a review. Clin. Child Fam.
Psychol. Rev. 15 (3), 192–214. https://doi.org/10.1007/s10567-012-0115-x.
Meyer, J.D., Crombie, K.M., Cook, D.B., Hillard, C.J., Koltyn, K.F., 2019. Serum
endocannabinoid and mood changes after exercise in major depressive disorder.
Med. Sci. Sports Exerc. 51 (9), 1909–1917. https://doi.org/10.1249/
MSS.0000000000002006.
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